Clinical Trial

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 23, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective single arm, phase II clinical trial to observe the efficacy and safety of orelabrutinib combined with pemetrexed in the treatment for patients with relapsed/refractory central nervous system lymphoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-01-22; most recent amendment 2025-04-18.
Status change: Not Yet Recruiting → Recruiting 2022-01-28
Trial Details
NCT Number NCT05209620
Lead Sponsor Henan Cancer Hospital
Conditions Central Nervous System Lymphoma
Enrollment 30 participants
Start Date 2021-12-21
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-12-21 (estimated)
Updated on ClinicalTrials.gov 2025-04-23